Vortioxetine hydrobromide is an antidepressant medication used to treat major depressive disorder [1]. It is also known by the brand name Trintellix [1].
How does vortioxetine hydrobromide work?
Vortioxetine hydrobromide is classified as a serotonin modulator and stimulator [1]. Its mechanism of action involves inhibiting the serotonin transporter, which increases serotonin levels in the brain. It also acts as a receptor agonist, antagonist, or partial agonist at various serotonin receptors, including 5-HT1A, 5-HT1B, 5-HT3, 5-HT1D, and 5-HT7 receptors [1]. This multifaceted action is believed to contribute to its antidepressant effects [1].
When can vortioxetine hydrobromide patents expire?
Information on the specific patent expiration dates for vortioxetine hydrobromide can be found on specialized drug patent databases [2]. For instance, DrugPatentWatch.com provides detailed patent information, including expiration timelines for various drugs [2].
What are the common side effects of vortioxetine hydrobromide?
Common side effects associated with vortioxetine hydrobromide include nausea, vomiting, diarrhea, constipation, and dizziness [1]. Some patients may also experience sexual dysfunction [1].
How does vortioxetine hydrobromide compare to other antidepressants?
Vortioxetine hydrobromide's unique pharmacological profile, affecting multiple serotonin receptors in addition to serotonin reuptake inhibition, differentiates it from some other classes of antidepressants like SSRIs and SNRIs [1]. Clinical studies have explored its efficacy and tolerability in comparison to other treatments for major depressive disorder [1].
Can generic versions of vortioxetine hydrobromide be developed?
The development of generic versions of vortioxetine hydrobromide is contingent on patent expiry and regulatory approval [2]. Once patents expire, pharmaceutical companies can seek approval to market generic equivalents, which typically leads to lower drug prices [2].
What is the regulatory status of vortioxetine hydrobromide?
Vortioxetine hydrobromide has received approval from regulatory agencies like the U.S. Food and Drug Administration (FDA) for the treatment of major depressive disorder [1].
What clinical data supports vortioxetine hydrobromide's use?
Clinical trials have demonstrated vortioxetine hydrobromide's efficacy in reducing depressive symptoms and improving cognitive function in patients with major depressive disorder [1]. These studies have also assessed its safety profile [1].
What are patient concerns regarding vortioxetine hydrobromide?
Patients often inquire about the effectiveness of vortioxetine hydrobromide for their specific symptoms, potential side effects, and the duration of treatment [1]. Discussions with healthcare providers typically address these concerns, including managing side effects and understanding the treatment course [1].
Where can I find more information on vortioxetine hydrobromide patents?
Detailed information regarding the patent landscape for vortioxetine hydrobromide, including expiration dates and any ongoing litigation, is available through dedicated pharmaceutical patent tracking services such as DrugPatentWatch.com [2].
What are the risks associated with vortioxetine hydrobromide?
Like other antidepressants, vortioxetine hydrobromide carries risks, including the potential for suicidal thoughts and behaviors, especially in younger adults [1]. It may also interact with other medications [1]. Patients should discuss all potential risks with their healthcare provider [1].
Who manufactures vortioxetine hydrobromide?
The original manufacturer of vortioxetine hydrobromide is Lundbeck and Takeda Pharmaceuticals [1].
Sources:
[1] https://www.trintellix.com/
[2] https://drugpatentwatch.com/